Definium Therapeutics (DFTX) awards 62,500 performance-based shares to Chief Commercial Officer

Rhea-AI Filing Summary

Definium Therapeutics, Inc. reported that Chief Commercial Officer Matthew T. Wiley acquired 62,500 common shares as a grant/award. According to the award terms, these shares represent the second tranche of performance share units granted effective March 17, 2025 and remain subject to vesting based on continued employment through March 17, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Wiley holds 237,133 common shares directly.

Insider Trade Summary

Net Buyer: 62,500 shares

Net Buy 1 txn

Insider Wiley Matthew T.

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	62,500	$0.00	$0.00

Holdings After Transaction: Common Shares — 237,133 shares (Direct)

Footnotes (1)

1. F1. The common shares represent the second tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

Key Figures

Shares awarded: 62,500 common shares Price per share for award: $0.0000 per share Shares held after transaction: 237,133 common shares +2 more

5 metrics

Shares awarded 62,500 common shares Grant/award acquisition reported for Matthew T. Wiley

Price per share for award $0.0000 per share Stated transaction price for the awarded common shares

Shares held after transaction 237,133 common shares Direct holdings of Matthew T. Wiley following the award

Vesting end date March 17, 2028 Date through which employment is required for vesting

Original grant effective date March 17, 2025 Effective date of performance share unit grant

Key Terms

performance share units, contingent right, clinical and regulatory milestones, Performance Share Unit Award Agreement

4 terms

performance share units financial

"The common shares represent the second tranche of performance share units granted effective March 17, 2025"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

contingent right financial

"Each performance share unit represented a contingent right to receive one common share"

clinical and regulatory milestones medical

"based on, and subject to, the achievement of certain clinical and regulatory milestones set forth"

Clinical and regulatory milestones are the key steps a medical product must clear as it is tested on patients and reviewed by government health authorities, such as completing major clinical trials, filing safety and effectiveness data, or receiving marketing approval. Investors watch these checkpoints like milestones on a roadmap because each one sharply changes the odds that a product will reach patients and generate revenue, much like a car passing inspection before it can be sold.

Performance Share Unit Award Agreement financial

"milestones set forth in the Performance Share Unit Award Agreement"

FAQ

What did Definium Therapeutics (DFTX) disclose about Matthew T. Wiley’s recent equity award?

Definium Therapeutics disclosed that Chief Commercial Officer Matthew T. Wiley received a grant of 62,500 common shares, issued as part of a performance share unit award and subject to future vesting conditions tied to employment and milestones.

How many Definium Therapeutics (DFTX) shares did Matthew T. Wiley acquire in this Form 4?

Matthew T. Wiley acquired 62,500 common shares in this reported transaction. The shares were awarded at a stated price of $0.0000 per share as part of a performance-based equity grant subject to vesting conditions.

What are the vesting conditions on Matthew T. Wiley’s new Definium Therapeutics (DFTX) share award?

The awarded shares remain subject to vesting based on Wiley’s continued employment through March 17, 2028 and the achievement of specified clinical and regulatory milestones described in the Performance Share Unit Award Agreement.

How many Definium Therapeutics (DFTX) shares does Matthew T. Wiley hold after this transaction?

After the reported award, Matthew T. Wiley holds 237,133 common shares of Definium Therapeutics directly. This figure reflects his position following the 62,500-share grant reported in the Form 4 filing.

What is the origin of the 62,500 Definium Therapeutics (DFTX) shares granted to Matthew T. Wiley?

The 62,500 common shares represent the second tranche of performance share units originally granted effective March 17, 2025, with each unit representing a contingent right to receive one common share upon meeting specific conditions.

Are Matthew T. Wiley’s new Definium Therapeutics (DFTX) shares fully earned at grant?

No. The common shares tied to this award remain subject to vesting. Vesting depends on Wiley’s continued employment through March 17, 2028 and on meeting defined clinical and regulatory milestones under the award agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 08:30 AM Accepted by SEC EDGAR 08/12/2026 - 08:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wiley Matthew T.

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/12/2026		A		62,500(1)	A	$0.00	237,133	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The common shares represent the second tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

	/s/Mark Sullivan, Attorney-in-Fact for Matthew T. Wiley	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)